aur109

AUR109 (formerly known as ODM-203) is an oral, spectrum-selective small molecule kinase inhibitor developed for oncology and fibrotic indications. It targets multiple kinases including fibroblast growth factor receptors (FGFRs), vascular endothelial growth factor receptors (VEGFRs), discoidin domain receptor 1 (DDR1), and salt-inducible kinase 2 (SIK2). By inhibiting these kinases, AUR109 exerts antitumor effects through both direct tumor cell inhibition and modulation of the tumor microenvironment. Preclinical studies have shown that it can decrease immune checkpoint expression such as PD-1 and PD-L1 on CD8 T cells and NK cells while increasing IFN-γ expression, suggesting potential synergy with immune checkpoint inhibitors. The drug is being evaluated in Phase II clinical trials for solid tumors including colorectal cancer, ovarian cancer, renal cell carcinoma/kidney cancer, hepatic fibrosis, general fibrosis, and FGFR-mutant bladder cancer[1][3][4][7][10].

Other names

n-[3-(2,4-difluorophenyl)-5-[5-(1-methylpyrazol-4-yl)benzimidazol-1-yl]phenyl]cyclopropanesulfonamide